Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
56
GYRE Quote, Financials, Valuation and Earnings
Last price:
$7.41
Seasonality move
:
12.42%
Day range:
$7.38 - $7.64
52-week range:
$6.11 - $13.75
Dividend yield:
0%
P/E ratio:
194.74x
P/S ratio:
6.81x
P/B ratio:
6.99x
Volume:
48.4K
Avg. volume:
91K
1-year change:
-23.08%
Market cap:
$712.9M
Revenue:
$105.8M
EPS (TTM):
$0.04
Analysts' Opinion
-
Consensus RatingGyre Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.00, Gyre Therapeutics, Inc. has an estimated upside of 143.24% from its current price of $7.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $7.40.
Fair Value
-
According to the consensus of 3 analysts, Gyre Therapeutics, Inc. has 143.24% upside to fair value with a price target of $18.00 per share.
GYRE vs. S&P 500
-
Over the past 5 trading days, Gyre Therapeutics, Inc. has overperformed the S&P 500 by 6.98% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Gyre Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gyre Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Gyre Therapeutics, Inc. reported revenues of $30.6M.
Earnings Growth
-
Gyre Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Gyre Therapeutics, Inc. reported earnings per share of $0.03.
Enterprise value:
689.5M
EV / Invested capital:
--
Price / LTM sales:
6.81x
EV / EBIT:
57.29x
EV / Revenue:
6.43x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1,365.30x
Price / Operating cash flow:
528.63x
Enterprise value / EBITDA:
48.11x
Gross Profit (TTM):
$102.4M
Return On Assets:
8.53%
Net Income Margin (TTM):
11.02%
Return On Equity:
10.4%
Return On Invested Capital:
10.26%
Operating Margin:
22.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $86.3M | $191.3M | $107.3M | $25.5M | $30.6M | |
| Gross Profit | $82.9M | $184M | $102.4M | $24.5M | $28.9M | |
| Operating Income | $19.6M | $44.7M | $12M | $4.2M | $6.9M | |
| EBITDA | $20.4M | $46.9M | $14.3M | $4.7M | $7.6M | |
| Diluted EPS | -$8.01 | -$0.95 | $0.04 | $0.01 | $0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $74M | $30.2M | $5.1M | $54.8M | $98.6M | |
| Total Assets | $78.5M | $31M | $10M | $125.2M | $159.4M | |
| Current Liabilities | $17.3M | $1.6M | $1.8M | $14.7M | $15.9M | |
| Total Liabilities | $17.8M | $1.6M | $6.4M | $26.8M | $22M | |
| Total Equity | $60.7M | $29.4M | $3.5M | $98.5M | $137.4M | |
| Total Debt | $550K | -- | -- | $1.1M | $539K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $64.8M | $36.7M | $2M | $1.7M | $5M | |
| Cash From Investing | -$90.3M | -$42.8M | -$4.3M | -$2.4M | -$1.2M | |
| Cash From Financing | $45M | $16.5M | $26.9M | $374K | $50K | |
| Free Cash Flow | $56.1M | $25.8M | -$505K | $980K | $4.3M | |
GYRE
Sector
Market Cap
$712.9M
$28.3M
Price % of 52-Week High
53.82%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
-3.94%
-1.59%
1-Year Price Total Return
-23.08%
-17.41%
Beta (5-Year)
2.906
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.30
200-day SMA
Sell
Level
$8.01
Bollinger Bands (100)
Sell
Level
7.31 - 8.09
Chaikin Money Flow
Sell
Level
-308.8K
20-day SMA
Sell
Level
$7.41
Relative Strength Index (RSI14)
Sell
Level
49.57
ADX Line
Buy
Level
12.41
Williams %R
Neutral
Level
-51.145
50-day SMA
Sell
Level
$7.61
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
49.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (24.0872)
Buy
CA Score
(Annual)
Level (0.3129)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-5.7433)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, GYRE has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GYRE average analyst price target in the past 3 months is $18.00.
-
Where Will Gyre Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gyre Therapeutics, Inc. share price will rise to $18.00 per share over the next 12 months.
-
What Do Analysts Say About Gyre Therapeutics, Inc.?
Analysts are divided on their view about Gyre Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gyre Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Gyre Therapeutics, Inc.'s Price Target?
The price target for Gyre Therapeutics, Inc. over the next 1-year time period is forecast to be $18.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GYRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gyre Therapeutics, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GYRE?
You can purchase shares of Gyre Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gyre Therapeutics, Inc. shares.
-
What Is The Gyre Therapeutics, Inc. Share Price Today?
Gyre Therapeutics, Inc. was last trading at $7.41 per share. This represents the most recent stock quote for Gyre Therapeutics, Inc.. Yesterday, Gyre Therapeutics, Inc. closed at $7.40 per share.
-
How To Buy Gyre Therapeutics, Inc. Stock Online?
In order to purchase Gyre Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GYRE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GYRE
Sector
P/E ratio
194.74x
24.24x
PEG ratio
--
-0.01x
P/B ratio
6.99x
1.84x
Price / LTM sales
6.81x
1.60x
Growth Metrics
GYRE
Sector
Revenue growth
19.92%
4.6%
Earnings growth
166.41%
10.71%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.19
Profitability
GYRE
Sector
Profitability FY 2024
$101.9M
$3.5M
Return on invested capital
10.26%
-32.04%
Return on assets
8.53%
-28.44%
Return on equity
10.4%
-38.09%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
6
Balance Sheet
GYRE
Sector
Total cash
$60M
$26.1M
Short term investments
$14.9M
$25.7M
Total assets
$125.4M
$76.4M
Long term debt
$539K
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
